Transient Azoospermia Induced by Valganciclovir Treatment for Cytomegalovirus Infection in a Reproductive Male After Kidney Transplant: A Case Report.

INTRODUCTION

Spermatogenic dysfunction is a side effect of valganciclovir, which is commonly used to treat cytomegalovirus infections. Here, we report the case of a reproductive man who underwent kidney transplantation and was diagnosed with azoospermia after valganciclovir treatment for cytomegalovirus infection.

CASE PRESENTATION: A 30-year-old man underwent an ABO-compatible living-donor kidney transplantation. Two months after the kidney transplant, the patient was diagnosed with cytomegalovirus infection and gastritis. Therefore, valganciclovir treatment was initiated. Two months after completion of valganciclovir treatment, the patient was diagnosed with azoospermia. Azoospermia induced by valganciclovir was suspected, and careful monitoring was performed. Nine months after azoospermia diagnosis, the sperm concentration improved to normal range (43.3 × 106/mL). Subsequently, the patient's wife conceived.

CONCLUSION

During valganciclovir treatment, careful monitoring and adequate informed consent are needed to support patients of reproductive age.